

## Obesity & Diabetes: A Review

Nagamani S\* and Naga pavan B

<sup>1</sup>Department of Pharmacy, CMR College of Pharmacy, JNTU University, Telangana

<sup>2</sup>Livestock Research Institute, CVSc,SVVU, Hyderabad, India

### Review Article

Received: 05/09/2016

Revised: 07/09/2016

Accepted: 09/09/2016

#### \*For Correspondence

Nagamani S, Department of Pharmacy, CMR College of Pharmacy, JNTU University, Telangana, India.

**Keywords** Weight loss, Obesity, Overweight

#### E-mail:

[nagamani194@gmail.com](mailto:nagamani194@gmail.com)

#### ABSTRACT

Worldwide obesity has become an epidemic with many obesity-associated health problems, such as cardiovascular disease, hypertension and type II diabetes. Cardiovascular disease still remains as the leading cause of death in women and obesity as the leading risk factor for type 2 diabetes. Obesity and diabetes mellitus, both are important independent risk factors for the development of cardiovascular diseases. Lifestyle, food habits, genetic makeup and environment play important roles in adipose tissue function or dysfunction. Obesity, chronic inflammation and insulin resistance leads to the development of type 2 diabetes and other complications related to obesity such as hepatic steatosis, obstructive sleep apnea, polycystic ovarian syndrome, etc.

This paper aims to describe the relationship between diabetes and obesity giving an overview of obesity and type 2 diabetes and their associated complications. This paper describes the epidemiology of both obesity and diabetes and their potential implications on health consequences.

### INTRODUCTION

Abnormal deposition of fat in the adipose tissue due to chronic over nutrition or reduced physical activity or hereditary reasons is called as obesity<sup>[1-3]</sup>. The etiology of obesity can be broadly attributed to the worsening lifestyle. This increase in obesity leads to multiple obesity-associated health complications mainly cardiovascular disease (CVD), type 2 diabetes mellitus (DM)<sup>[4-8]</sup>, and hypertension (HTN), and most of the times these diseases occur altogether. This type of clustering disease conditions are often called as metabolic syndrome<sup>[9-13]</sup>. Still it is unclear at which the obesity associated complications begin. Whether obesity is the lone culprit or any other underlying factors such as inflammation is the primary cause is still unknown clearly. Hence, clear understanding of the role of fat deposition in appetite stimulation<sup>[14-18]</sup>, inflammation, hormone secretion etc. is critical in the development of prevention strategies and treatment for the obesity associated complications.

#### *Adipose Tissue*

Most of adipose tissue is made up of fat storing cells adipocytes<sup>[19-22]</sup> which are held together by collagen fibers. Other cells of adipose tissue<sup>[23-28]</sup> include pre-adipocytes<sup>[29-31]</sup>, leukocytes, stromal-vascular cells and macrophages. Adipose tissue is the storage site for body's fuel which will be mainly in the form of triglycerides<sup>[32-35]</sup>. Mammalian adipose tissue is of two types namely white adipose tissue (WAT) and brown adipose tissue. Most of the fat in obese people will be stored as WAT. While Brown adipose tissue is mainly used for body heat regulation by means of thermogenesis, heat insulation etc. Adipose tissue acts as buffer during energy imbalances and adipocytes numbers is mainly controlled by apoptosis and are generated when required from pre-adipocytes and progenitor cells.

Adipose tissue plays an important role in many homeostatic processes such as energy expenditure, immune response, thyroid function, bone health maintenance, blood clotting, and reproduction and in regulation of some hormonal pathways through the secretion of free fatty acids, adipin, adiponectin, etc. Any disturbance in normal signaling or deficiency of the signaling proteins will result in severe complications.

#### *Effects of Increasing Adiposity*

Increase in adipocytes size and number disturbs the complex interactions of Growth and reproductive hormones and the feedback allosteric mechanism are disturbed. This creates the disturbance in feedback

mechanism for energy intake and expenditure, physical activity [36-40] which delineates the body's inability of accommodating the chronic overfed state. This Chronic over-nutrition leads to proinflammatory cytokine secretion and suppression of anti-inflammatory<sup>[41-44]</sup> protein sections leading to metabolic derangements insulin resistance<sup>[45-49]</sup> and diabetes.

### **Insulin Resistance**

In obese adults glucose<sup>[50]</sup> disposal will be reduced especially at the level of skeletal muscle and impairment of insulin action in fatty acid oxidation can be seen. This leads to insulin resistance and abnormal lipolysis. But the level of obesity for the onset these complications are not yet determined. Some studies have shown that the secretion rates of insulin are higher in obese people when compared with the normal individuals and even there is no significant difference in insulin clearance and hepatic insulin extraction between obese and non-obese individuals. Many studies have shown that obese children with normoinsulinaemia are found with insulin resistance the non-esterified fatty acids<sup>[51-53]</sup> response to insulin infusion is similar in both obese and non-obese children.

Several studies have shown that the loss of excess body weight<sup>[54-58]</sup> can reduce the skeletal muscle, whole body, and hepatic insulin resistance and metabolism indicating a strong relationship between glucose regulation and weight loss (Adipose tissue reduction). But the mechanism for obesity-induced insulin resistance is not known clearly yet. Some scientist found that the Retinol-binding protein-4 which is secreted by the adipose tissue potentially induces insulin resistance by reducing phosphatidylinositol-3-OH kinase signaling in the muscles; and by increasing the expression of phosphoenolpyruvate carboxykinase in the liver cells.

Many scientists demonstrated that, insulin resistance improves the regional adipose-specific insulin resistance which does not improve with weight loss which may be due to the irreversible GLUT-4 translocation in adipose tissue. This mechanism provides us a molecular link between obesity and fat or glucose dysregulation. Hence it can be concluded that the earliest negative effects of obesity is insulin resistance development.

### **Healthy obese**

Even though obesity is linked to many complications but it is not likely that every time a direct relationship exists between obesity and diabetes<sup>[59-60]</sup>. Around 20% of the obese people are healthy without diabetes and its comorbidities. Healthy obese people are insulin sensitive and will have intimal medial thicknesses, less skeletal muscle and hepatic fat as seen in normal weight individuals giving healthy obese people an advantage of low risk of diabetes and its associated comorbidities when compared to other same weight obese peoples.

### **Management**

Repercussions of obesity can be effectively managed by Weight loss<sup>[61-67]</sup> which can be achieved through modifications in lifestyle like regular physical activity and dietary adjustments. These kind of lifestyle modifications not only minimize the treatment costs but also reduces the pill and injection burdens which will give psychological strength to the persons. Recently many studies have shown that Bariatric surgery [68-74] is very effective than lifestyle modifications and safer than the usual pharmacological treatments.

### **Nutritional Management**

Diet management is of primary importance in preventing diabetes or managing existing diabetes and preventing or slowing diabetic complications. Calorie intake must be in accordance with the goals of weight management of the individual. Macro and micronutrients<sup>[75]</sup> intake should be precise and must be according to the metabolic status and lipid profile of the patient. However there is no evidence-based recommendation for the micronutrient supplements.

### **Exercise for Obese**

Regular exercise effectively manages the glycemic control in diabetes. As physical activity reduces the insulin resistance Insulin, which is the e is the major cause for the hyperglycemia<sup>[76-80]</sup> in obese diabetics, Regular exercise along with yoga is highly recommended. Physical activity will improve insulin resistance through the reduction of free fatty acid-induced hepatic insulin resistance<sup>[81-85]</sup>. Moreover the weight loss achieved by regular exercise improves hepatic insulin sensitivity is better than the weight loss induced through calorie restriction<sup>[86-92]</sup>. Exercises are proved to increase skeletal muscle glucose uptake and utilization. Physical exercise also increases muscle insulin sensitivity which can be effective in blood glucose<sup>[93-99]</sup> level management by the body.

### CONCLUSION

Obesity and diabetes are one the major problems faced by the modern man. The study of the link between the two conditions is very important because obesity is the major risk factor for type 2 diabetes. The prevalence of obesity and diabetes along with associated complications increases the costs to society.

### REFERENCES

1. Chalupova L, et al. CTRP1: A Molecular Link between Obesity and Hypertension . J Mol Biomark Diagn. 2016;7:289.
2. Brettfeld C, et al. Integration and Weighing of Omics Data for Obesity. J Diabetes Metab. 2016;7:690.
3. Rohmah Z, et al. Anti-Obesity effects of Lipid Extract from Sea-Reared of Rainbow Trout (*Oncorhynchus mykiss*) Fed with Sea Squirt (*Halocynthia roretzi*) Tunic's Carotenoids and CLA. J Nutr Food Sci. 2016;6:525.
4. Rachel C, et al. The -765G>C Cyclooxygenase-2 Promoter Polymorphism is associated with Type 2 Diabetes Mellitus, Low High-density Lipoprotein and Manifest Angina. J Diabetes Metab. 2016;7:686.
5. Bayramova AN. Gastroenterological Diseases as a Complications of Type 2 Diabetes Mellitus. J Gastrointest Dig Syst. 2016;6:442.
6. Szybinski Z. Primary Prevention of Obesity and Type 2 Diabetes Mellitus. Epidemiology (Sunnyvale). 2016;6:243.
7. Demchuk MP, et al. Efficacy of Fetal Stem Cells use in Complex Treatment of Patients with Insulin-resistant Type 2 Diabetes Mellitus. J Stem Cell Res Ther. 2016;6:342.
8. Cakir OO. Visceral Fat Volume is a Better Predictor for Insulin Resistance than Abdominal Wall Fat Index in Patients with Prediabetes and Type 2 Diabetes Mellitus. Intern Med. 2016;6:220.
9. Tiihonen K, et al. Effect of Dietary Betaine on Metabolic Syndrome Risk Factors in Asian. J Diabetes Metab. 2016;7:692.
10. Prakaschandra R, et al. Are Common Polymorphisms of the Lipoprotein Lipase and Human Paraoxonase-1 Genes Associated with the Metabolic Syndrome in South African Asian Indians?. J Clin Exp Cardiol. 2016;7:452.
11. Suarez J and Díaz-Juárez J. Post-translational Modifications of Proteins in Metabolic Syndrome. J Metabolic Syndr. 2016;5:e117.
12. Miller B and Fridline M. Metabolic Syndrome Prevalence and Risk in the United States based on NHANES 2001-2012 Data. J Metabolic Syndr. 2016;5:203.
13. Berezin AE. Non-Classical Progenitor Mononuclears in Metabolic Syndrome: The Role of Serum 25-Hydroxyvitamin D3. Clin Med Biochemistry Open Access. 2016;2:115.
14. Nikkhah A. Standardizing Appetite through Timing of Food Intake to Minimize Metabolic Disorders: A Veterinary Revelation. J Veterinar Sci Technol. 2015;6:e116.
15. Joharishirazi M and Chehilmard D. Study of the Impact of Knowledge Deployment and Appetite for Change on Work. J Account Mark. 2015;3:120.
16. Nikkhah Akbar. Evolutionary Co-Emergence of Appetite and Hormonal Rhythms: A Molecular Highway to Overpass Obesity. J Biodivers Biopros Dev. 2015;1:e105.
17. Docx MKF, et al. Food Refusal, Loss of Appetite, Chronic Fatigue and Depression due to Central Adrenal Insufficiency Presenting as Anorexia Nervosa in an Adolescent Girl. J Clin Case Rep. 2013;3:310.
18. Uneyama H, et al. Perceived Palatability and Appetite for Protein by Umami Taste Derived from Glutamate. J Nutr Food Sci. 2012;S10:007
19. Kikuchi H, et al. Thermo-Sensitive Transient Receptor Potential Vanilloid (TRPV) Channels Regulate IL-6 Expression in Mouse Adipocytes. Cardiol Pharmacol. 2016;4:156.
20. Pinto H, et al. Isolated Rat Adipocytes are Still Capable of Inducing Lipolysis after a Lipocryolysis-Like Thermic Stimulus. J Glycomics Lipidomics. 2014;4:122.
21. Hu B, et al. Bioassay-guided Isolation of the Antidiabetic Active Principle from *Salvia miltiorrhiza* and its Stimulatory Effects on Glucose Uptake Using 3T3-L1 Adipocytes. Med chem. 2014;4:592-597.
22. Machii N, et al. Resistin Exacerbates Insulin Resistance under the Condition of Low Adiponectin in 3T3-L1 Adipocytes. J Diabetes Metab. 2012;3:230.

23. Panneerselvam S, et al. Protective Effect of Soy Isoflavones (from *Glycine max*) on Adipose Tissue Oxidative Stress and Inflammatory Response in an Experimental Model of Post-menopausal Obesity: The Molecular Mechanisms. *Biochem Anal Biochem*. 2016;5:266.
24. Lounsbury EA, et al. Adipose Tissue Hypoxia: Effects on Metabolism and Insulin Sensitivity. *J Nutr Food Sci*. 2016;6:488
25. Fazaeli H, et al. Introducing of a New Experimental Method in Semen Preparation: Supernatant Product of Adipose Tissue: Derived Mesenchymal Stem Cells (SPAS). The Patient's Perspective. *JFIV Reprod Med Genet*. 2016;4:178.
26. Murata D, et al. Osteochondral Regeneration of the Loading-bearing Site Using a Scaffold Free Three-dimensional Construct of Adipose Tissue-derived Mesenchymal Stem Cells in Pigs. *J Tissue Sci Eng*, 2016;7:165.
27. Okura H, et al. Spermine Treated-Adipose Tissue-Derived Multi-Lineage Progenitor Cells Improve Left Ventricular Dysfunction in a Swine Model of Chronic Myocardial Infarction. *J Stem Cell Res Ther*. 2016;6:326.
28. Tachida Y, et al. Proteomic Comparison of the Secreted Factors of Mesenchymal Stem Cells from Bone Marrow, Adipose Tissue and Dental Pulp. *J Proteomics Bioinform*. 8;266-273.
29. Tang W, et al. White fat progenitor cells reside in the adipose vasculature. *Science*. 2008;322:583–586.
30. Knittle J, Timmers K, Ginsberg-Fellner F, Brown RE, Katz DP. The growth of adipose tissue in children and adolescents. *J Clin Invest*. 1979;63:239–246.
31. Ailhaud G. Adipose cell differentiation in culture. *Mol Cell Biochem*. 1982;49:17–31.
32. Heidari A. Molecular Dynamics and Monte-Carlo Simulations for Replacement Sugars in Insulin Resistance, Obesity, LDL Cholesterol, Triglycerides, Metabolic Syndrome, Type 2 Diabetes and Cardiovascular Disease: A Glycobiological Study. *J Glycobiol*. 2016;5:e111.
33. ang S, et al. Magnitude of the Difference between Fasting and Non-fasting Triglycerides, and Its Dependent Factors Running Title: Fasting and Non-fasting Triglycerides. *J Community Med Health Educ*. 2015;5:375.
34. Jansen EHJM, et al. Long Term Stability of Parameters of Lipid Metabolism in Frozen Human Serum: Triglycerides, Free Fatty Acids, Total-, HDL- and LDL-cholesterol, Apolipoprotein-A1 and B. *J Mol Biomark Diagn*. 2014;5:182.
35. Iozzo P. Viewpoints on the way to the consensus session. Where does insulin resistance start? The adipose tissue. *Diabetes Care*. 2009;32 Suppl 2:S168–S173.
36. Nodine PM, et al. The Impact of Physical Activity on Sleep during Pregnancy: A Secondary Analysis. *Clinics Mother Child Health*. 2016;13:245
37. Barbosa HC and Oliveira ARD. Physical Activity of Preschool Children: A Review. *Physiother Rehabil*. 2016;1:111
38. Hayashi A and Sukanuma N. Physical Activity for Gestational Diabetes Mellitus. *Clinics Mother Child Health*. 2016;13:238.
39. Löllgen H. Prevention by Physical Activity: The Relevance of Physical Activity and Fitness. *J Yoga Phys Ther*. 2016;6:e123.
40. Albugami HF. Conducting Physical Activity Intervention Afterward School Times: A Meta-analysis. *J Obes Weight Loss Ther*. 2016;6:311.
41. Arabatzi F, et al. Physical Activity, Physical Fitness and Overweight in Early Schoolchildren. *J Sports Med Doping Stud*. 2016;6:178.
42. Kravchenko IA, et al. Anti-Inflammatory Activity of the Sea Coastal Lake Salt in a Combination to Ultrasound. *Biosens J*. 2015;4:119.
43. Liu H, et al. Anti-diabetes and Anti-inflammatory Activities of Phenolic Glycosides from *Liparis odorata*. *Med chem (Los Angeles)*. 2016;6:500-505.
44. Kamau JK, et al. Anti-Inflammatory Activity of Methanolic Leaf Extract of *Kigelia Africana* (Lam.) Benth and Stem Bark Extract of *Acacia Hockii* De Wild in Mice. *J Dev Drugs*. 2016;5:156.
45. Kahn SE, et al. Mechanisms linking obesity to insulin resistance and type 2 diabetes. *Nature*. 2006;444:840–846.
46. Shoelson SE, et al. Inflammation and insulin resistance. *J Clin Invest*. 2006;116:1793–1801
47. Cakir OO, et al. Visceral Fat Volume is a Better Predictor for Insulin Resistance than Abdominal Wall Fat Index in Patients with Prediabetes and Type 2 Diabetes Mellitus. *Intern Med*. 2016;6:220.

48. Heidari A. Molecular Dynamics and Monte–Carlo Simulations for Replacement Sugars in Insulin Resistance, Obesity, LDL Cholesterol, Triglycerides, Metabolic Syndrome, Type 2 Diabetes and Cardiovascular Disease: A Glycobiological Study. *J Glycobiol.* 2016;5:e111.
49. Moreira HP, et al. HIV-Positive Inflammatory Activity Monitoring Correlated to Peripheral Insulin Resistance - Hire Study. *HIV Curr Res.* 2016;1:101.
50. Ouyang J and Ochs RS. Involvement of Amp Kinase in Glucose Uptake and Palmitate Oxidation in L6 Muscle Cell Cultures. *Metabolomics.* 2014;4:133.
51. Lumeng CN, et al. Increased inflammatory properties of adipose tissue macrophages recruited during diet-induced obesity. *Diabetes.* 2007;56:16-23.
52. Canello R, et al. Reduction of macrophage insulin resistance and adipose tissue infiltration and chemoattractant gene expression changes in white adipose tissue of morbidly obese subjects after surgery-induced weight loss. *Diabetes.* 2005;54:2277-2286.
53. Mahmoud AS, et al. *Corchorus Olitorius* Linn: A Rich Source of  $\Omega$ 3-Fatty Acids. *Pharm Anal Acta.* 2016;7:486.
54. Faghri P and Buden J. Health Behavior Knowledge and Self-efficacy as Predictors of Body Weight. *J Nutr Disorders Ther.* 2015;5:169
55. Birketvedt GS, et al. A Dietary Supplement in Combination with an Education Plan and a Long-Term Follow-up Significantly Decrease Blood Pressure, Body Weight and Body Fat. *J Nutr Food Sci.* 2016;6:512.
56. de Luis DA, et al. Effects of Polymorphism rs3123554 in the Cannabinoid Receptor Gene Type 2 (*Cnr2*) on Body Weight and Insulin Resistance after Weight Loss with a Hypocaloric Mediterranean Diet. *J Metabolic Synd.* 2016;5:199.
57. Kristensen NB and Pedersen O. Targeting Body Weight Regulation with Probiotics: A Review of Randomized Trials in Obese and Overweight People Free of Co-morbidities. *J Nutr Food Sci,* 2015;5:422.
58. Esposito T, et al. Correlation between Thyroid Endocrine Status, Change in Body Weight and Macular Thickness in Obese Patients. *Gen Med (Los Angel).* 2015;3:206.
59. Gargiulo C, et al. Human Peripheral Blood Stem Cells can be a Solution to Diabetes Mellitus Type 2 a Preliminary Study on 14 Patients. *J Stem Cell Res Ther.* 2015;6:354.
60. Chobanyan N, et al. Evaluation of Environmental Risk Factors for Type 2 Diabetes in Sint Maarten. *J Environ Anal Toxicol.* 2016;6:386.
61. Ferone A, et al. Sera of Overweight Patients Alter Adipogenesis and Osteogenesis of Bone Marrow Mesenchymal Stromal Cells, a Phenomenon that also Persists in Weight Loss Individuals. *J Stem Cell Res Ther.* 2016;6:347.
62. Goizueta-San-Martín G, et al. Nerve Compression Secondary to Weight Loss. *Int J Neurorehabilitation.* 2016;3:213.
63. Kastelan S, et al. Body mass index: a risk factor for retinopathy in type 2 diabetic patients. *Mediators Inflamm.* 2013;2013:436329.
64. e Luis DA, et al. Effects of Polymorphism rs3123554 in the Cannabinoid Receptor Gene Type 2 (*Cnr2*) on Body Weight and Insulin Resistance after Weight Loss with a Hypocaloric Mediterranean Diet. *J Metabolic Synd.* 2016;5:199.
65. Lauschke JL and Major G. Acute Paraspinal Compartment Syndrome Related to Use of Proprietary Weight Loss Product, by a Patient with Sodium Channelopathy. *J Spine.* 2016;S7:001.
66. Anton K, et al. Weight Loss Following Left Gastric Artery Embolization in a Human Population without Malignancy: A Retrospective Review. *J Obes Weight Loss Ther.* 2015;5:285.
67. Goni I. A Short Communication on Strategy for Weight Loss Based on Healthy Dietary Habits and Control of Emotional Response to Food. *J Obes Weight Loss Ther.* 2015;5:281.
68. Busetto L, et al. Visceral fat loss evaluated by total body magnetic resonance imaging in obese women operated with laparoscopic adjustable silicone gastric banding. *Int J Obes.* 2000;24:60–69.
69. ias JC, et al. Inflammatory Polyneuropathy after Bariatric Surgery: Report of Two Cases. *J Neurol Disord.* 2016;4:278.
70. Livadariu RM, et al. Upper Digestive Endoscopy Prior to Bariatric Surgery in Morbidly Obese Patients - A Retrospective Analysis. *Journal of Surgery [Jurnalul de chirurgie].* 2016;12:19-21
71. Abiad F, et al. Bariatric Surgery in the Management of Adolescent and Adult Obese Patients with Polycystic Ovarian Syndrome. *J Obes Weight Loss Ther.* 2016;6:303.

72. Pouwels S, et al. The Necessity of Preoperative Pulmonary Function Screening in Patients Scheduled for Bariatric Surgery. *J Obes Weight Loss Ther.* 2016;6:295.
73. Boesten RHM, et al. Social- Demographic and Behavioural Characteristics of a Morbid Obese Population Seeking Bariatric Surgery. *J Obes Weight Loss Ther.* 2015;5:290.
74. Aldeen T and Adewale A. Obesity and Psoriasis: Can Bariatric Surgery Trigger Psoriasis? . *J Clin Exp Dermatol Res.* 2015;6:302.
75. Khan MS, et al. Hidden Deficiency of Micronutrients in Apparently Healthy Children of District Bannu, Khyber Pakhtunkhwa, Pakistan. *Biochem Pharmacol (Los Angel).* 2015;4:172.
76. Finta KM, et al. Urine Sodium excretion in response to an oral glucose tolerance test in obese and nonobese adolescents. *Pediatrics.* 1992;90:442-446.
77. Steinberger J, et al. Relationship between insulin resistance and abnormal lipid profile in obese adolescents. *J Pediatr.* 1995;126:690-695.
78. Shimomura I, et al. Enhanced expression of PAI-1 in visceral fat: possible contributor to vascular disease in obesity. *Nat Med.* 1996;2:800-803.
79. Wong WT, et al. Endothelial dysfunction: the common consequence in diabetes and hypertension. *J Cardiovasc Pharmacol.* 2010;55:300-307.
80. Stefan N, et al. Identification and characterization of metabolically benign obesity in humans. *Arch Intern Med.* 2008;168:1609-1616.
81. Hex N, et al. Estimating the current and future costs of Type 1 and Type 2 diabetes in the UK, including direct health costs and indirect societal and productivity costs. *Diabet Med.* 2012;29:855-62.
82. Tuomilehto J, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. *N Engl J Med.* 2001;344:1343-50.
83. Li G, et al. The long-term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: a 20-year follow-up study. *Lancet.* 2008;371:1783-9.
84. The 10-year cost-effectiveness of lifestyle intervention or metformin for diabetes prevention: an intent-to-treat analysis of the DPP/DPPOS. *Diabetes Care.* 2012;37:723-30.
85. Maggard-Gibbons M, et al. Bariatric surgery for weight loss and glycemic control in nonmorbidly obese adults with diabetes: a systematic review. *Jama.* 2013;309:2250-61.
86. Dirani M, Xie J, et al. Are obesity and anthropometry risk factors for diabetic retinopathy? The diabetes management project. *Invest Ophthalmol Vis Sci.* 2011;52:4416-21.
87. Lim LS, et al. C-reactive protein, body mass index, and diabetic retinopathy. *Invest Ophthalmol Vis Sci.* 2010;51:4458-63.
88. Vamos EP, et al. Changes in the incidence of lower extremity amputations in individuals with and without diabetes in England between 2004 and 2008. *Diabetes Care.* 2010;33:2592-7.
89. Eckel RH, et al. Obesity and type 2 diabetes: what can be unified and what needs to be individualized? *Diabetes Care.* 2011;36:1424-1430.
90. Neeland IJ, et al. Dysfunctional adiposity and the risk of prediabetes and type 2 diabetes in obese adults. *Jama.* 2012;308(11):1150-9.
91. Holman N, et al. The Association of Public Health Observatories (APHO) Diabetes Prevalence Model: estimates of total diabetes prevalence for England, 2010-2030. *Diabetic Medicine.* 2011;28:575-82.
92. Kodama S, et al. Quantitative relationship between body weight gain in adulthood and incident type 2 diabetes: a meta-analysis. *Obes Rev.* 2014;15:202-14.
93. Abdullah A, et al. The duration of obesity and the risk of type 2 diabetes. *Public Health Nutr.* 2011;14:119-26.
94. Vinciguerra F, et al. Very severely obese patients have a high prevalence of type 2 diabetes mellitus and cardiovascular disease. *Acta Diabetol.* 2013;50:443-9.
95. Freemantle N, et al. How strong is the association between abdominal obesity and the incidence of type 2 diabetes? *Int J Clin Pract.* 2008;62:1391-6.
96. Despres JP. Body fat distribution and risk of cardiovascular disease: an update. *Circulation.* 2012;126:1301-13.
97. Kahn SE, et al. Mechanisms linking obesity to insulin resistance and type 2 diabetes. *Nature.* 2006;444:840-6.

## Research & Reviews: Journal of Pharmaceutical Quality Assurance

98. Gambineri A, et al. Polycystic ovary syndrome is a risk factor for type 2 diabetes: results from a long-term prospective study. *Diabetes*. 2012;61:2369-74.
99. Reis JP, et al. Lifestyle factors and risk for new-onset diabetes: a population-based cohort study. *Ann Intern Med*. 2011;155:292-9.